Linomide (roquinimex) affects the balance between pro- and anti- inflammatory cytokines in vitro in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 98, Issue 2, 1998, Pages 94-101

  Tian, W Z ^a   Navikas, V ^a   Matusevicius, D ^a   Soderstrom M ^a   Fredrikson, S ^a   Hedlund, G ^b   Link, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Pharmacia & Upjohn AB   (Sweden)

Author keywords

Cytokines; Linomide; Multiple sclerosis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; ROQUINIMEX; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOMODULATION; IN SITU HYBRIDIZATION; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS;

EID: 0031858371     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1998.tb01726.x     Document Type: Article

References (48)

1. NAVIKAS V, LINK H. Cytokines in the pathogenesis of multiple sclerosis. J Neurosci Res 1996: 45: 322-33.
2. ROTT O, FLEISCHER B, CASH E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994: 24: 1434-40.
3. CRISI GM, SANTAMBROGGIO L, HOCHWALD GM, SMITH SR, CARLINO JA, THORBECKE GL. Staphylococcal enterotoxin B and tumor-necrosis factor-alpha-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-beta and interleukin-10. Eur J Immunol 1995: 25: 3035-40.
4. INOBE JI, CHEN J, WEINER HL. In vivo administration of IL-4 induces TGF-beta-producing cells and protects animals from experimental autoimmune encephalomyelitis. Ann NY Acad Sci 1996: 778: 390-2.
5. KALLAND T, ALM G, STALHANDSKE T. Augmentation of mouse natural killer activity by LS-2616, a new immunomodulator. J Immunol 1985: 134: 3956-61.
6. LARSSON EL, JOKI A, STALHANDSKE: T. Mechanism of action of the new immunomodulator LS2616 on T cell responses. Int J Immunopharmacol 1987: 9: 425-31.
7. KALLAND T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J Immunol 1990: 144: 4472-6.
8. TARKOWSKI A, GUNNARSSON K, NILSSON LA, LINDHOLM L, STALHANDSKE T. Successful treatment of autoimmunity in MRL/mice with LS-2616, a new immunomodulator. Arthritis Rheum 1986: 29: 1405-9.
9. KARUSSIS DM, LEHMANN D, SLAVIN S et al. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide. Ann Neurol 1993: 34: 654-60.
10. KARUSSIS DM, LEHMANN D, SLAVIN S et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 1993: 90: 6400-4.
11. GROSS DJ, SIDI H, WEISS L, KALLAND T, ROSENMANN E, SLAVIN S. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologia 1994: 37: 1195-201.
12. ANDERSEN O, LYCKE J, TOLLESSON PO et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996: 47: 895-900.
13. KARUSSIS DM, MEINER Z, LEHMANN D et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator Linomide - a double blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996: 47: 341-6.
14. SCHUMACHER GA, BEEBE G, KIBLER RF et al. Problem of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965: 122: 552-68.
15. KURTZKE JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983: 33: 1444-52.
16. TIBBLING, G, LINK H, ÖHMAN S. Principles of albumin and IgG analysis in neurological diseases. I. Establishment of reference values. Scand J Clin Lab Invest 1977: 37: 385-90.
17. KOSTULAS VK, LINK H, LEFVERI AK. Oligoclonal IgG bands in cerebrospinal fluid: principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch Neurol 1987: 44: 1041-4.
18. DEIBLER GE, MARTENSSON RE, KIES MV. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem 1972: 2: 139-65.
19. JOSEPH IB, ISAACS JT. The antiangiogenic agent Linomide inhibits tomor necrosis factor-alpha secretion via inhibition of its synthesis. Prostate 1996: 29: 183-90.
20. ARAD G, KATZENELLENBOGEN M, LEVY R, SLAVIN S, KAEMPFER R. Linomide, an immunomodulator that inhibits Th1 cytokine gene expression. Int Immunol 1996: 8: 1603-7.
21. LINK J, SÖDERSTRÖM M, OLSSON T, HÖJEBERG B, LJUNGDAHL Å, LINK H. Increased IFN-γ, IL-4 and TGF-β in multiple sclerosis. Ann Neurol 1994: 36: 379-86.
22. GRAY PW, LEUNG DW, PENNICA D et al. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature 1982: 295: 503-8.
23. GRAY PW, AGGARWAL BB, BENTON CV et al. Cloning and expression of cDNA for human lymphotoxin, lymphokine with tumor necrosis activity. Nature 1984: 312: 721-4.
24. PENNICA D, NEDWIN GE, HAYFLICK JS et al. Human tumor necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 1984: 312: 452-7.
25. YOKOTA T, OTSUKA T, MOSMANN TR et al. Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell and T-cell stimulating activities. Proc Natl Acad Sci USA 1986: 83: 5898-608.
26. VIEIRA P, DE WAAL-MALEFYT R, DANG M-N et al. Isolation and expression of human cytokine synthesis inhibitory factor (CSIF/IL-10) cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 1991: 88: 1172-6.
27. DERYNCK R, JARETT JA, CHEN EY et al. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 1985: 316: 701-5.
28. OLSSON T, WANG WZ, HÖLEBERG B et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen induced secretion of interferon-gamma. J Clin Invest 1990: 86: 981-5.
29. LINK J, SÖDERSTRÖM M, LJUNGDAHL Å et al. Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology 1994: 44: 728-34.
30. SÖDERSTRÖM M, LINK H, SUN JB et al. T cells recognizing multiple peptides of myelin basic protein are found in blood and enriched in cerebrospinal fluid in optic neuritis and multiple sclerosis. Scand J Immunol 1993: 37: 355-68.
31. NAVIKAS V, LINK J, PALASIK W et al. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand J Immunol 1995: 41: 171-8.
32. NAVIKAS V, HE B, LINK J et al. Augmented expression of tumor necrosis factor-α and lymphotoxin mRNA in mononuclear cells in multiple sclerosis and optic neuritis. Brain 1996: 119: 213-3.
33. DUIJVESTIJN AM, SCHREIBER AB, BUTCHER EC. Interferon-gamma regulates an antigen specific for endothelial cells involved in lymphocyte traffic. Proc Natl Acad Sci USA 1986: 83: 9114-18.
34. STEINIGER B, VAN DER MEIDE PH. Rat ependyma and microglia cells express class II MHC antigens after intravenous infusion of recombinant gamma interferon. J Neuroimmunol 1988: 19: 111-18.
35. MALE D, PRYCE G. Induction of Ia molecules on brain endothelium is related to susceptibility to experimental allergic encephalomyelitis. J Neuroimmunol 1989: 21: 87-90.
36. SELMAJ K, RAINE CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988: 21: 339-46.
37. SELMAJ K, RAINE CS, CANNELLA B, BROSNAN CF. Cytokine cytotoxicity against oligodendrocytes: apoptosis induced by lymphotoxin. J Immunol 1991: 147: 1522-9.
38. VARTANIAN T, LI Y, ZHAO M, STEFANSSON K. Interferon-γ-induced oligodendrocyte cell death: Implications for the pathogenesis of multiple sclerosis. Mol Med 1995: 1: 732-42.
39. FIORENTINO DF, ZLOTNIK A, VIEIRA P et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991: 146: 3444-51.
40. VAN DER WEEN RC, STOHLMAN SA. Encephalitogenic Th1 cells are inhibited by Th2 cells with related peptide specificity: relative roles of interleukin (IL)-4 and IL-10. J Neuroimmunol 1993: 48: 213-20.
41. 2: cytokines with identical immunosuppressive effects and a potential role in the regulation of autoimmune T-cell function. J Neuroimmunol 1989: 24: 249-58.
42. 1. J Immunol 1991: 146: 3012-16.
43. LINK J, HE B, NAVIKAS V et al. TGF-β suppresses autoantigen-induced expression of proinflammatory cytokines but not of IL-10 in multiple sclerosis and myasthenia gravis. J Neuroimmunol 1995: 58: 21-35.
44. GONZALO J, GONZALEZ-GARCIA A, KALLAND T, HEDLUND G, MARTINEZ C, KROEMER G. Linomide, a immunomodulator that prevents death in four models of septic shock. Eur J Immunol 1993: 23: 2372-4.
45. LEUTWYLER C, SCHALCH L, JUNGI TW. Evidence for interleukin-1 beta being a necessary but not sufficient co-stimulatory signal in monocyte-dependent anti-CD3-mediated T-cell triggering. Immunol Lett 1993: 38: 33-9.
46. + T cells to immobilized anti-TCR monoclonal antibody. J Immunol 1994: 152: 1618-28.
47. LA MANTIA L, EOLI M, MILANESE C, SALMAGGI A, DUFOUR A, TORRI V. Double-blind trial of dexamethazone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol 1994: 34: 199-203.
48. + T cells in vitro. J Immunol 1996: 156: 2406-12.